Efficacy of early screening for prostate cancer in an elderly patient with absence of urinary symptoms but a manifestation of a rare symptom: a case report

M. R. J. Salman; A. H. Jalal

doi:10.18203/2394-6040.ijcmph20223268

Authors

M. R. J. Salman Qatar University Health Centre PHCC, Doha, Qatar
A. H. Jalal Leabaib Health Centre PHCC, Doha, Qatar

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20223268

Keywords:

Prostate cancer, Early screening, Elderly, Obese, Constipation, No urinary symptoms

Abstract

This is a case report of an unusual symptom of prostate cancer, constipation seen in an elderly 81-year-old patient. The patient was initially referred for physiotherapy for concerns involving his lumbosacral spines. Following which, he attended the clinic again with the same symptoms of back pain and constipation and was immediately referred for prostate cancer screening. The patient did not have urinary symptoms. Despite a number of factors that point towards aggressive prostate cancer, the patient was screened early and further investigation led to identifying his cancer. This allowed for the patient to undergo early prostate cancer treatment and is presently cancer free. This is a report to underline the importance of early prostate cancer screening in elderly men who present without the key concern of urinary symptoms.

Metrics

Metrics Loading ...

References

Ferlay J, Colombet M, Soerjomataram I. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149:778-89.

Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.

McHugh J, Saunders EJ, Dadaev T. Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. Br J Cancer. 2022;126:1366-73.

Ko YH, Kim BH. Should Contemporary Western Guidelines Based on Studies Conducted in the 2000s Be Adopted for the Prostate-Specific Antigen Screening Policy for Asian Men in the 2020s? World J Mens Health. 2022;40(4):543-50.

Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. Int J Urol. 2018;25(6):524-31.

Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol. 2010;183(5):1792-6.

Odedina FT, Akinremi TO, Chinegwundoh F. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agent Cancer. 2009;4(1):S2.

Odedina FT, Ogunbiyi JO, Ukoli FA. Roots of prostate cancer in African-American men. J Natl Med Assoc. 2006;98(4):539-43.

Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Molecular Sci. 2020;21(14):5036.

Hjelmborg JB, Scheike T, Holst K. The Heritability of Prostate Cancer in the Nordic Twin Study of Cancer, The Heritability of Prostate Cancer. Cancer Epidemiol Biomarkers Prevent. 2004;23(11):2303-10.

Roser M, Ortiz-Ospina E, Ritchie H. Life Expectancy, 2013. Available at: https://ourworldin data.org/life-expectancy. Accessed on 9 November 2022.

Life Expectancy and Healthy Life Expectancy Data by WHO Region. Global Health Observatory Data Repository, 2020. Available at: https://apps.who.int/gho/data/view.main.SDG2016LEXREGv?lang=en Accessed 10 November 2022.

Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at Diagnosis and Age at Death in Familial Prostate Cancer. Oncologist. 2009;14:1209-17.

Brassell SA, Rice KR, Parker PM. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol. 2011;185(1):132-7.

Langlais, Crystal S. Obesity at diagnosis and prostate cancer prognosis and recurrence risk following primary treatment by radical prostatectomy. Cancer Epidemiol Biomarkers Prevent. 2019;1917-25.

Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res. 2011;4(4):486-501.

Ibrahim A, Abou Khatwa S, Atta M, Ashry M, Ismail A. Determination of a Cut-off Point for Prostatic Specific Antigen to Avoid Unjustified Biopsy Among Asymptomatic Elderly Men. J High Institute Publ Heal. 2018;48(1):30-5.

Gnanapragasam VJ, Greenberg D, Burnet N. Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes. BMC Med. 2022;20:264.

Frånlund M, Carlsson S, Stranne J, Aus G, Hugosson J. The absence of voiding symptoms in men with a prostate‐specific antigen (PSA) concentration of ≥3.0 ng/ml is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial. BJU Int. 2012;110(5):638-43.

NHS. Prostate cancer: symptoms, 2021. Available at: https://www.nhs.uk/conditions/prostate-cancer/symptoms/. Accessed on 10 November 2022.

Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800-9.

Elabbady A, Kotb AF. Unusual presentations of prostate cancer: A review and case reports. Arab J Urol. 2013;11(1):48-53.

Lee B. Why Can’t He Go? An Unusual Case of Constipation. Am J Gastroenterol. 2018;113:S920.

You J. Computed tomography and magnetic resonance imaging findings of metastatic rectal linitis plastica from prostate cancer: A case report and review of literature. World J Clin Cases. 2018;554.